Company intelligence / Profile preview

Locemia Solutions

Montreal, Quebec, Canadalocemia.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 3

Overview

Locemia Solutions developed an innovative, needle-free intranasal glucagon powder for the emergency treatment of severe hypoglycemia. The company’s lead program reached Phase III before being acquired by Eli Lilly in 2015. The product has since been commercialized as Baqsimi®.

Therapeutic areas: Endocrinology
Modalities: Small molecule (glucagon nasal powder)
Industry: Biotech

Drug pipeline

1 asset

glucagon

Phase 3

Indications: Severe hypoglycemia

Partnerships

Acquired by and partnered with Eli Lilly and Company for commercialization

Beyond the preview

Go deeper on Locemia Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Locemia Solutions.

Explore the full profile